131I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital-Reference-Cited by-同舟云学术

131I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital

Published:2003-08 Issue:4 Volume:18 Page:513-524
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Turner J. Harvey¹,Martindale Andrew A.¹,Boucek Jan¹,Claringbold Phillip G.²,Leahy Michael F.³

Affiliation:

1. Department of Nuclear Medicine, Fremantle Hospital and Department of Medicine, The University of Western Australia, Fremantle, Western Australia

2. Department of Oncology, Fremantle Hospital and Department of Medicine, The University of Western Australia, Fremantle, Western Australia

3. Department of Haematology, Fremantle Hospital and Department of Medicine, The University of Western Australia, Fremantle, Western Australia

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/108497803322287583

Reference19 articles.

1. Update: A Revolution in the Treatment of Non-Hodgkin's Lymphoma

2. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

3. Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

4. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients;Cancer Biotherapy and Radiopharmaceuticals;2024-06-01

2. Deregulated transcription factors in the emerging cancer hallmarks;Seminars in Cancer Biology;2024-01

3. Theranostics in Australia: The Importance of Vision and Training, and the Power of Collaboration;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

4. Theranostics of Hematologic Disorders;Nuclear Medicine and Immunology;2021-11-25

5. Combination radionuclide therapy: A new paradigm;Nuclear Medicine and Biology;2021-07